Compare Amphastar Pharmaceuticals Inc (AMPH) vs Nutanix Inc (NTNX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Nutanix Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Nutanix Inc trades at $63.85 (market cap $17.42B). The key difference: Nutanix Inc is far larger — about 20.2× Amphastar Pharmaceuticals Inc's market cap, and Nutanix Inc is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | NTNX | |
|---|---|---|
Market Cap | $863.95M | $17.42B |
Sector | Health | Technology |
52-Week High | $30.81 | $81.12 |
52-Week Low | $16.87 | $34.41 |
Enterprise Value | $1.26B | $16.94B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Nutanix (NTNX) trades at $62.67, up 4.24% today, with strong technical and fundamental momentum. The stock is near its 52-week high, supported by bullish moving averages and consistent earnings beats. Revenue growth is robust, with 2026 revenue projected at $2.7B and net profit margin improving to 10.03%. Recent news highlights institutional buying and positive analyst coverage, with 62.5% of analysts rating it a Buy.
Outlook remains positive due to earnings momentum and institutional interest, but risks include high valuation multiples and competitive pressures. The consensus price target is $57.80, slightly below current levels, suggesting near-term consolidation may occur. Investors should weigh growth prospects against elevated P/E and P/S ratios.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Nutanix Inc
Nutanix, Inc. is a global leader in cloud software and hyperconverged infrastructure (HCI) solutions. The company's platform converges computing, virtualization, and storage into a single, seamless software-defined solution, enabling private, hybrid, and multi-cloud environments. Nutanix helps organizations simplify data center operations, manage their applications across various cloud platforms, and reduce IT complexity, positioning it as a key enabler of modern hybrid cloud strategies.
Read more on NTNX →
